STUDY OF CAMPATH-1H COMBINED WITH MMF AND SIROLIMUS (PC01)

CAMPATH-1H 联合 MMF 和西罗莫司的研究 (PC01)

• 批准号: 7607267
• 负责人: WILLIAM E. HARMON
• 金额: $ 23.02万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607267
• 关键词: Calcineurin inhibitor; Cessation of life; Chronic; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Monoclonal Antibody Campath-1H; Research; Research Personnel; Resources; Safety; Sirolimus; Source; Steroids; Transplantation; Treatment Protocols; United States National Institutes of Health; fluorouracil/methotrexate/mitoxantrone protocol; mycophenolate mofetil; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective To evaluate the safety of Campath-1H post-transplantation when given as part of a multitherapy regimen to prevent graft loss and death and to avoid steroids and chronic use of calcineurin inhibitors.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主要目的 评价Campath-1H作为多种治疗方案的一部分在移植后的安全性，以预防移植物丢失和死亡，避免类固醇和长期使用钙调磷酸酶抑制剂。